Multimodal treatment strategies for patients with rectal cancer are increasingly including the
possibility of organ preservation, through nonoperative management or local excision …

Background Radical surgery via total mesorectal excision might not be the optimal first-line
treatment for early-stage rectal cancer. An organ-preserving strategy with selective total …

Objective To provide an evidence-based guide for the MRI interpretation of complete tumor
response after neoadjuvant chemoradiation therapy (CRT) for rectal cancer using visual …

Importance A watch-and-wait approach for patients with rectal cancer and a clinical
complete response after neoadjuvant chemoradiotherapy or radiotherapy is associated with …

Simple Summary This prospective phase II–III randomized trial explores the value of modern
technology for prudent radiation dose escalation in the curative management of patients with …

Purpose: Peposertib—an orally administered DNA-dependent protein kinase inhibitor—has
shown potent radiosensitization in preclinical models. This dose-escalation study …

Simple Summary An individualized treatment approach is necessary to improve survival and
quality of life in rectal cancer. Tools to stratify patients are missing, but ctDNA seems to be a …

Purpose To compare treatment plans of two different rectal boost strategies: up-front versus
adaptive boost at the 1.5 T MR-Linac. Methods Patients with locally advanced rectal cancer …

Introduction Organ preservation is associated with superior functional outcome and quality
of life (QoL) compared with total mesorectal excision (TME) for rectal cancer. Only 10% of …

Abstract Background Circulating tumor DNA (ctDNA) is an emerging biomarker for locally
advanced rectal cancer (LARC), giving hope for stratified treatment. As the completed …